Dario Beltran, MD
Sleep Medicine · Midland, TXNPI 1912100850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 241 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,350, 6.3 times the $214 reported in 2019.
Across 241 payments — averaging $19.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$552
- AbbVie$529
- UCB, Inc.$422
- Novartis$413
- Teva Pharmaceuticals USA, Inc.$349
- SK Life Science, Inc.$330
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,782100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $552 |
| AbbVie(2 entities) | 30 | $529 |
| UCB, Inc. | 18 | $422 |
| Novartis | 25 | $413 |
| Teva Pharmaceuticals USA, Inc. | 18 | $349 |
| SK Life Science, Inc. | 16 | $330 |
| Amgen(2 entities) | 14 | $275 |
| Biogen | 11 | $216 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $213 |
| Otsuka America Pharmaceutical, Inc. | 8 | $192 |
| Lundbeck LLC | 6 | $160 |
| Amneal Pharmaceuticals LLC | 7 | $125 |
| Genentech USA, Inc. | 6 | $124 |
| Lilly USA, LLC | 5 | $104 |
| Argenx US, Inc. | 4 | $93 |
| Supernus Pharmaceuticals, Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 3 | $72 |
| Averitas Pharma Inc. | 3 | $65 |
| Harmony Biosciences LLC | 4 | $63 |
| Eisai Inc. | 2 | $59 |
| EMD Serono, Inc. | 2 | $51 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| AstraZeneca | 2 | $47 |
| Livanova USA, Inc. | 2 | $43 |
| Sanofi | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $27 |
| CSL Behring | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $18 |
How this compares
$4,782 in reported general payments places this provider in the 75th percentile of 112 sleep medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 32 | $46,828 |
| RexultiBrexpiprazole | 22 | $38,368 |
| Emgality PenGalcanezumab-Gnlm | 33 | $21,739 |
| Memantine Hcl | 410 | $11,972 |
| Memantine Hcl ErMemantine Hcl | 26 | $5,233 |
| Carbamazepine ErCarbamazepine | 19 | $2,956 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 22 | $2,421 |
| Levetiracetam | 101 | $2,263 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 48 | $2,075 |
| Donepezil Hcl | 160 | $1,749 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,567 |
| Gabapentin | 99 | $1,404 |
| Primidone | 27 | $1,124 |
| Valproic Acid | 18 | $895 |
| Lamotrigine | 27 | $639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $552 | $46,82832 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $192 | $38,36822 claims |
| Upsher-smith Laboratories LLCTopiramate | $18 | $39253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 112 sleep medicine providers in Texas.
Other sleep medicine in Midland
- Manoher GurruMidland$8K
- Gerard MeskillSugar Land$1M
- Vikas JainFrisco$673K
- Amit VermaHouston$493K
- Jerald SimmonsHouston$165K
- James AndrySan Antonio$100K
- William BurkesBeaumont$99K
- Ashwin GowdaAustin$71K
- John DebusDallas$38K
- Peter ObessoTyler$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.